These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 34079038

  • 1. BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors.
    Hernández-Breijo B, Navarro-Compán V, Plasencia-Rodríguez C, Parodis I, Gehin JE, Martínez-Feito A, Novella-Navarro M, Mezcua A, Warren DJ, Nozal P, Pascual-Salcedo D, Balsa A.
    Sci Rep; 2021 Jun 02; 11(1):11632. PubMed ID: 34079038
    [Abstract] [Full Text] [Related]

  • 2. Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.
    Mori A, Saito T, Takahashi M, Shibata M, Tsuji G, Hatachi S, Takahashi S, Kumagai S.
    PLoS One; 2020 Jun 02; 15(12):e0243729. PubMed ID: 33315881
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
    Ulijn E, den Broeder N, Wientjes M, van Herwaarden N, Meek I, Tweehuysen L, van der Maas A, van den Bemt BJ, den Broeder AA.
    Ann Rheum Dis; 2020 Jul 02; 79(7):867-873. PubMed ID: 32317314
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. No Correlation between Anti-drug Antibodies and Therapeutic Response in Tunisian Patients with Chronic Inflammatory Diseases Treated by TNF Blockers.
    Bouden S, Laadhar L, Soua J, Ben Messaoud M, Rouached L, Ayadi I, Saidane O, Ben Tekaya A, Mahmoud I, Rekik S, Srairi HS, Tekaya R, Bellakhal S, Fekih M, Abdelmoula L, Kallel M.
    Curr Rheumatol Rev; 2024 Jul 02; 20(4):435-443. PubMed ID: 38314598
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.
    Balsa A, Sanmarti R, Rosas J, Martin V, Cabez A, Gómez S, Montoro M.
    Rheumatology (Oxford); 2018 Apr 01; 57(4):688-693. PubMed ID: 29365183
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B, Chen CI, Proudfoot C, Shinde S, Kuznik A, Wei W.
    Adv Ther; 2017 Nov 01; 34(11):2422-2435. PubMed ID: 29039054
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C, Tzioufas A, Goules A, Kourlaba G, Theodoratou T, Christou P, Maniadakis N.
    Rheumatol Int; 2017 Sep 01; 37(9):1441-1452. PubMed ID: 28523420
    [Abstract] [Full Text] [Related]

  • 19. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors.
    Bodio C, Grossi C, Pregnolato F, Favalli EG, Biggioggero M, Marchesoni A, Murgo A, Filippini M, Migliorini P, Caporali R, Pellerito R, Ciccia F, Sarzi-Puttini P, Perosa F, Paolazzi G, Hollan I, Bendtzen K, Meroni PL, Borghi MO.
    Autoimmun Rev; 2020 May 01; 19(5):102509. PubMed ID: 32173513
    [Abstract] [Full Text] [Related]

  • 20. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG, Sinigaglia L, Becciolini A, Grosso V, Gorla R, Bazzani C, Atzeni F, Sarzi Puttini PC, Fusaro E, Pellerito R, Caporali R.
    Int J Rheum Dis; 2018 Feb 01; 21(2):422-430. PubMed ID: 29082659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.